Chairman & CEO
Missing a competitor? Contribute!
Endo is one of Grunenthal's top competitors. Endo was founded in 1997 in Ballsbridge, County Dublin. Like Grunenthal, Endo also operates in the Pharmaceuticals industry. Endo generates $1.2B more revenue than Grunenthal.
UCB is a top competitor of Grunenthal. UCB was founded in 1928, and is headquartered in Brussels, Brussels-Capital Region. UCB operates in the Biotechnology industry. UCB generates $5B more revenue vs. Grunenthal.
Salix Pharmaceuticals is seen as one of Grunenthal's top competitors. Salix Pharmaceuticals is headquartered in Bridgewater, New Jersey, and was founded in 1989. Like Grunenthal, Salix Pharmaceuticals also competes in the Pharmaceuticals field. Salix Pharmaceuticals generates 63% the revenue of Grunenthal.
Trending News for Grunenthal and Grunenthal's Competitors
Mestex is a Switzerland-based biotech company that develops and commercializes investigational medicines for the treatment of osteoarthritis.
Averitas Pharma, Inc.
Averitas Pharma is a pharmaceutical company that researches and develops novel therapeutics for the non-opioid treatment of acute pain.
Adhesys Medical GmbH
Adhesys is a medical device company that focuses on developing polyurethane-based surgical sealants for emergency procedures.
Thar Pharmaceuticals Inc
Thar Pharmaceuticals researches, discovers, develops and commercializes oral therapies for serious and life threatening conditions.
Almirall de Mexico
These are all the companies that Grunenthal has acquired. Grunenthal has acquired 5 companies and its latest acquisition was Mestex AG in Apr 2021. Mestex is a Switzerland-based biotech company that develops and commercializes investigational medicines for the treatment of osteoarthritis.
Grunenthal Funding History
No recent funding data found related to Grunenthal
No recent investments found related to Grunenthal
These are all the companies that Grunenthal has invested in. Grunenthal has invested 5 companies and its latest investment was Mestex AG in Apr 2021. Mestex is a Switzerland-based biotech company that develops and commercializes investigational medicines for the treatment of osteoarthritis.
April 23, 2021MarketScreener
announces pricing of its first bond
(marketscreener.com) DGAP-News: Grünenthal GmbH / Key word: Bond Grünenthal announces pricing of its ... See more » April 15, 2021Global Legal Chronicle
Grnenthal GmbH's Acquisition of Mestex AG
Homburger advises Grünenthal GmbH on this matter. Grünenthal GmbH announced the acquisition of Mestex... See more » April 14, 2021startupticker
Grnenthal acquires Swiss biotech company Mestex
With the acquisition of Mestex AG, Grünenthal secures global rights for an attractive late-stage asse... See more » April 6, 2021FinanzNachrichten
Grnenthal is Recognized for its Strong Management of Environmental, Social and Governance (ESG) Risks
- Leading global ESG ratings agency Sustainalytics notes Grünenthal is in the top five percent among ... See more » February 12, 2021FinanzNachrichten
Grnenthal successfully extends its term loan bank facilities
AACHEN, Germany, Feb. 12, 2021 /PRNewswire/ -- Grünenthal has announced the successful extension of i... See more » February 10, 2021Markets Insider
Grnenthal closes deal with AstraZeneca for European rights to CRESTOR (rosuvastatin)
AACHEN, Germany, Feb. 10, 2021 /PRNewswire/ -- Grünenthal today announced the successful completion o... See more » February 8, 2021Royal Pharmaceutical Society
Grnenthal Ltd, Palexia 20 mg/ml Oral Solution
Grünenthal Ltd has informed the Medicines and Healthcare products Regulatory Agency (MHRA) that it is... See more »
Grunenthal Press Releases
Grunenthal Group is a research and development pharmaceutical company that focuses on pain treatments. Grunenthal was founded in 1946. Grunenthal's headquarters is located in Aachen, North Rhine-Westphalia, DE 52099.
Grunenthal's Chairman & CEO, Gabr... Grunenthal's Chairman & CEO, Gabriel Baertschi, currently has an approval
rating of 76%. Grunenthal's primary competitors are Endo, UCB & Salix Pharmaceuticals.
Frequently Asked Questions about Grunenthal
When was Grunenthal founded?Grunenthal was founded in 1946
Who is Grunenthal's CEO?Grunenthal's CEO is Gabriel Baertschi
How much revenue does Grunenthal generate?Grunenthal generates $1.6B in revenue
How much funding does Grunenthal have?Grunenthal has historically raised $0 in funding
Where is Grunenthal's headquarters?Grunenthal's headquarters is in Aachen North Rhine-Westphalia, DE
How many employees does Grunenthal have?Grunenthal has 4,500 employees
What sector does Grunenthal operate in?Grunenthal is in Pharmaceuticals
Who are Grunenthal's competitors?Grunenthal's top competitors are Endo, UCB, Salix Pharmaceuticals